IGF1 and myeloid sarcoma: have shown that reactive astrocytes from MS lesions display an increased IGFBP2 reactivity, and in vitro treatment of cultured astrocytes with IGFBP2 and IGF-1 enhances their proliferation, suggesting that in MS, IGFBP2 may serve to enhance reactive astrogliosis (55).